R Squared’s Olema Pharmaceuticals OLMA Stock Holding History

R Squared’s Portfolio OLMA Stock Details OLMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-750	Closed	-$4.37K	–	1111
2024 Q4	$4.37K	Buy	+750	New	+$7.49K	﹤0.01%	1341

Other funds holding OLMA

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LMC

Lightspeed Management Company Menlo Park, California $988M AUM 7.5% 1-Year Est. Return

R Squared's OLMA Position: Q1 2025 in Review

R Squared sold out of Olema Pharmaceuticals (OLMA) in Q1 2025, closing a stake of 750 shares — an estimated $4.37K sold.

R Squared first reported a position in OLMA in Q4 2024 and held it in 1 quarter. The position peaked at $4.37K in Q4 2024. 133 funds tracked by Wall St. Rank hold OLMA as of Q1 2025.

R Squared reported no remaining Olema Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
R Squared sold 750 Olema Pharmaceuticals shares in Q1 2025, an estimated $4.37K.
R Squared first reported a position in Olema Pharmaceuticals in Q4 2024 and held it in 1 quarter.
R Squared's Olema Pharmaceuticals position peaked at $4.37K in Q4 2024.
133 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.